Objectives: There is limited evidence regarding the long-term efficacy of regenerative treatment for peri-implantitis. The aim of this study was to evaluate a combination therapy of deproteinized bovine bone mineral with 10% collagen (DBBMC), enamel matrix derivative (EMD) and Doxycycline in the regeneration of bone defects associated with peri-implantitis.
| INTRODUC TI ON
Peri-implantitis is defined as an inflammatory process affecting the surrounding peri-implant tissues, resulting in loss of supporting bone (Zitzmann & Berglundh, 2008) . The reported prevalence of periimplantitis varies depending on the defining criteria used, ranging from 6.6% over a 9-10 year observation period (Mombelli, Müller, & Cionca, 2012; Roos-Jansaker et al., 2006) to 36.6% after an average of 8 years of implant loading (Atieh, Alsabeeha, Faggion, & Duncan, 2013; Koldsland, Scheie, & Aass, 2010) . Given the increasing numbers of implants being placed, a predictable and effective treatment for peri-implantitis is urgently required.
Laboratory and clinical studies point to a similar pathogenesis between periodontitis and peri-implantitis, and hence, similar approaches to management have been advocated (Heitz-Mayfield, 2008; Heitz-Mayfield & Lang, 2010; Meffert, 1996) . However, human biopsy results show that the apical extension of the inflammatory infiltrate relative to the alveolar bone crest is more pronounced in peri-implantitis than in periodontitis, suggesting that peri-implantitis may progress faster than periodontitis and/or the lesion may be less contained (Berglundh, Zitzmann, & Donati, 2011; Carcuac & Berglundh, 2014; Heitz-Mayfield & Lang, 2010) . The potentially accelerated nature of the disease progression around implants suggests the need for a more "aggressive" treatment approach to periimplantitis than periodontitis. Indeed, it was concluded at the Sixth European Workshop on Periodontology that non-surgical therapy alone seems to be insufficient in the treatment of most cases of peri-implantitis and surgical therapy is often required (Lindhe et al., 2008) .
The available literature on the management of peri-implantitis focuses on anti-infective treatments which involve non-surgical or surgical debridement and decontamination followed by ongoing supportive therapy (Heitz-Mayfield & Mombelli, 2012; HeitzMayfield et al., 2012 HeitzMayfield et al., , 2016 or regeneration of the peri-implant bone defect (Esposito, Grusovin, & Worthington, 2012; Heitz-Mayfield & Mombelli, 2012) . However, the details of the protocol in relation to the implant surface decontamination approach and the regenerative materials used are still open to debate. Numerous implant regenerative surgical therapy studies, including the use of bone grafts/ bone substitutes with and without membranes, have reported clinical and radiographic improvements for at least 3 years (Behneke, Behneke, & D'Hoedt, 2000; Froum, Froum, & Rosen, 2012 , 2015  Roos-Jansåker, Lindahl, Persson, & Renvert, 2011; Schwarz et al., 2009 Schwarz et al., , 2017 Schwarz, Hegewald, John, Sahm, & Becker, 2013) . These clinical studies used different grafting materials; thus, it was difficult to draw conclusions in regards to which method is superior (Esposito et al., 2012) , but no currently available methods are able to achieve predictably successful outcomes, and hence, further research is required in relation to the regenerative treatment of peri-implantitis (Esposito et al., 2012) .
There are limited studies that report on the use of biologically active materials such as enamel matrix derivative (EMD) to improve the performance of osteoconductive bone grafts (Froum et al., 2015; Isehed et al., 2016) . The purpose of the present clinical case series was to evaluate the 3-year clinical and radiographic results of combined osteoconductive deproteinized bovine bone mineral with 10% collagen (DBBMC), EMD and the topical antibiotic Doxycycline for surgical regenerative therapy of peri-implantitis.
| MATERIAL S AND ME THODS
This study was designed as a prospective cohort study in compliance with the STROBE checklist.
| Patient selection
Thirty consecutive patients (age range 20-70) referred for peri-implantitis were recruited to participate in the study. The inclusion criteria were:
1. Systemically healthy, non-smokers.
2.
Adequate oral home care.
3.
Patients who completed the pre-surgical phase of periodontal treatment that involved full-mouth ultrasonic debridement and manual curettage which resulted in FMBS below 20%.
4.
Only one implant affected with peri-implantitis, exhibiting a "crater-like" or circumferential defect, a bleeding/suppurating pocket of >4 mm, minimum 20% alveolar bone loss and in function for at least 2 years. Exclusion criteria were:
1. Patients with uncontrolled diabetes.
Taking bisphosphonate medications.
3. Pregnant or lactating females.
| Ethics approval
All patients received a detailed explanation of the surgical procedures and objectives of the study and signed an informed consent form prior to being included in the study. The Griffith University 
| Pre-surgical phase
All patients received full-mouth ultrasonic debridement and manual curettage as needed (with or without local anaesthesia) 4-6 weeks before the surgical protocol was performed. All patients reached full-mouth plaque score (FMPS) and full-mouth bleeding scores (FMBS) below 20% before proceeding with the surgical treatment.
| Preparation of combined grafting material
In a sterile dish, deproteinized bovine bone mineral with 10% collagen (DBBMC) (Bio-Oss Collagen, Geistlich, Switzerland) was mixed with 0.35 ml of enamel matrix derivative (EMD) (EMDOGAIN, Straumann, Basel, Switzerland) for 15 min (Figure 1a-d ). One capsule of Doxycycline 100 mg was added to the DBBMC, and EMD and the cocktail of materials were mixed until a homogenous material was formed. The rationale for using this treatment cocktail was to harness the reported beneficial effects of each of these materials in the management of peri-implantitis-the osteoconductive and space maintenance properties of DBBMC (Roccuzzo, Gaudioso, Lungo, & Dalmasso, 2016) , the wound healing enhancement capacity of EMD (Isehed et al., 2016; Miron, Oates, Molenberg, Dard, & Hamilton, 2010) and the antibiotic and immunomodulatory effects of Doxycycline (Golub et al., 2016) .
| Surgical phase
All surgical procedures were performed under local anaesthesia (Lidocaine HCL 2% with 1:100,000 epinephrine) and oral sedation (Diazepam 5-10 mg, one hour prior to procedure) by the same experienced periodontist (F.M.) (Figure 2a-d ). An intra-sulcular incision at the affected implant was made using a 15C blade (Swann-Morton, Sheffield England), and the flap was extended distally, with a vertical releasing incision made one to two teeth away from the affected implant. After flap elevation and removal of granulation tissue, the exposed implant threads were debrided using a fine tip low-power ultrasonic scaler (Cavitron SPS, Dentsply, York, PA, USA). The implant surface was dried with gauze, and 24% ethylenediaminetetraacetic acid (EDTA) (Prefgel, Switzerland) was applied to all exposed threads for 2 min. The surfaces were then washed with saline solution. The prepared cocktail of materials was applied to all the exposed threads. Primary closure was performed using a coronally advanced flap (CAF), and a connective tissue graft was added if 
| Clinical measurements
The following clinical parameters were measured with a periodontal probe (Hu-Friedy R , Hu-Friedy Mfg. Co, LLC, USA) at baseline, 12, 24 and 36 months:
1. Periodontal recession (REC): distance between the implant-abutment and gingival margin (GM) at the mid-buccal aspect of the implant.
Probing depth (PD)
: distance between the GM and the base of the deepest pocket of the implant.
Buccal Keratinized Tissue (KT)
: distance between GM and mucogingival junction at the mid-buccal aspect of the implant.
A second clinician who was not involved in the surgical procedure recorded all clinical parameters using 3.5× magnification. A calibrating exercise was performed to achieve intra-examiner reproducibility: Fullmouth charting of the same five patients was carried out at a weekly interval for three consecutive weeks. Calibration was confirmed when the measurements were consistently accurate to 0.5 mm.
| Radiographic measurement
Radiographs using a standardized long-cone paralleling technique
x-ray holder (XCP-DS ® x-ray holder, Chicago, USA) were taken preoperatively, 12, 24 and 36 months after treatment (Figure 3a-d) . The same x-ray machine (Kodak 2200 intra-oral X-ray unit, Trophy, Cedex 2 France, operated at 70 kVp, 15 mA,.14 s.) was used as the source of radiation for all images. The change in bone level (mm and % bone level) as a result of the treatment was measured by comparing the distance between the abutment-implant junction and the bone level at the mesial and distal surfaces pre-operatively with that at 12, 24
and 36 months post-regenerative therapy. The radiographic measurements were also carried out by the clinician who was not involved in the surgical procedure.
| Post-operative care
Patients were instructed not to brush the surgical sites for 2 weeks.
All patients were advised to take an analgesic (combined Paracetamol 500 mg and Ibuprofen 150 mg), as needed. All patients were given a post-operative kit containing 0.12% chlorhexidine digluconate mouthwash, surgical brush and 0.12% chlorhexidine gel. The mouthwash was used twice a day for the first week, and the surgical brush and chlorhexidine gel were applied to the treated area during the second and third weeks post-operatively.
| Supportive periodontal therapy
The implants were reviewed, and supportive periodontal therapy (SPT) was provided at 3, 6, and 12 months, and then every 4 months thereafter. The SPT protocol included full-mouth ultrasonic debridement (Cavitron SPS, Dentsply, York, PA, USA) and prophylactic clean and polish with rubber cap and pumice (Nupro ® , Denstply, Victoria, Australia). Additional manual curettage (with or without local anaesthesia) using Gracey curettes (Hu-Friedy R , Chicago, USA) and ultrasonic instruments was performed on the affected implant or dentition if there was BoP/suppuration. The patients were recalled after 1 week, 3 weeks, the 3rd month, 6th month and every 4 months thereafter.
| Successful treatment outcome criterion (STOC)
A composite criterion to determine whether an implant was successfully treated and did not need further surgical intervention was followed (Heitz-Mayfield & Mombelli, 2014) . Specifically, the proposed success criteria at the 36th month were:
1. Implant with deepest PD of <5 mm.
2.
No further bone loss >10%.
No BoP or suppuration.
4. Recession of <0.5 mm for anterior implants (aesthetic criterion) and < 1.5 mm for posterior implants (cleansability criterion, i.e., the more titanium threads exposed after treatment, the harder it is for the patient to keep the implant clean). 
| Statistical analyses
A paired t test was used to assess the differences in the clinical parameters between baseline and 12, 24 and 36 months. A p < .01 was considered to be significant.
| RE SULTS

| Patient and implant attributes
Thirty consecutive systemically healthy patients (with 30 peri-implantitis affected implants) completed the study (Table 1 ). The female to male ratio was 2:1 and the mean age of patients treated was 44.9 (± 11). The majority of the treated implants were located posteriorly with almost half located on the mandibular arch (40%). Most of the treated implants were micro-rough surface implants (Table 1 ).
All patients enrolled in the study maintained a low FMPS and FMBS of less than 20%.
| Implant survival
All 30 implants that were treated in this study survived and were functioning at the 36 months post-surgical review. There were statistically and clinically significant improvements in bone level, probing depth and percentage BoP from baseline, which were maintained at 12, 24 and 36 months after surgical treatment.
| Clinical parameters
| Bone level changes
The peri-implantitis treated in this study can be considered moderate to advanced with a mean bone loss prior to treatment of 6.92 mm (±1.26) (57% ± 16.5) ( 
| Probing depth
The mean depth of the deepest peri-implant pocket of each implant (PD) at the initial visit was 8.9 mm (±1.9). This mean PD reduced significantly to 3.55 mm (±0.49) by 12 months post-treatment and was maintained at 3.50 mm (±0.50) at 24 and 36 months after the regenerative therapy. The difference in the probing depth from pretreatment to 12, 24 and 36 months post-treatment was statistically significant (p < .01).
| Recession
The mean recession at the initial visit was 0.16 mm (±0.14). This recession remained stable at 0.15 mm (±0.12) at 12 and 24 months.
After 36 months, the mean recession levels slightly increased to 0.22 mm (±0.19). The difference in the recession level from baseline to 12, 24 and 36 months was not statistically significant.
| Bleeding on probing and suppuration
All of the patients achieved a FMBS and FMPS of less than 20%
at every review visit. In terms of bleeding/suppuration percentage at the treated implants, 100% of the implants treated had BoP at baseline (Figure 4 ). This dropped to 20% at the 3rd month review 
TA B L E 1 Patient and implant distributions
TA B L E 2 Clinical parameters
and reduced further to 10% at the 6th month maintenance visit. The maintenance period was increased to 6 months because of the stability achieved after the first 6 months of healing. The percentage of implants with BOP/suppuration increased to 50% after an additional 6 months (12-month follow-up) without peri-implant maintenance.
Subsequently, four monthly SPT was performed from the 12th to 36th month after surgical treatment. This led to a reduction in implants presenting with BOP and suppuration (Figure 4) , which was observed to be 20% at both the 24-and 36-month reviews.
| Success criterion
At 36 months after regenerative therapy, 56.7% of the implants treated were considered successful (Table 3) . On the other hand, 43.3% of the treated implants failed to achieve the success criterion.
The most common cause of failure 36 months after treatment was persistence of BoP (six implants, 20%) and radiographic evidence of further interproximal bone loss (four implants, 13%). Also, contributing to the treatment failure rate were the anterior implants with gingival recession greater than 0.5 mm (two implants, 6.66%) and posterior implants with greater than 1.5 mm gingival recession (one implant, 3.33%).
| D ISCUSS I ON
This study reports on a cohort of 30 consecutive patients suffering from peri-implantitis who were treated using a regenerative surgical protocol utilizing commercially available products. The result of this study showed that the approach of using the combination of DBBMC-EMD-Doxycycline is effective in the regenerative treatment of moderate to advanced peri-implantitis, with maintenance of the positive outcomes for a 3-year period.
The present case series found statistically significant improvement in PD, BL and BoP % after 12, 24 and 36 months. This PD reduction is similar to Froum et al. (2012) , who combined an osteoconductive bone graft with biologically active material (EMD/PDGF) and reported a PD reduction of 5.10 mm (±2.20). In the present study, it is possible that DBBMC acted as a delivery vehicle for longer or sustained release of EMD in the peri-impantitis defect, potentially enhancing its biological effectiveness in promoting healing within the peri-implant defect.
Published case series and RCTs that used bone graft alone without biologically active materials, such as xenograft (Roccuzzo et al., 2016 (Roccuzzo et al., , 2011 Further follow-up of the same patients 7 years after surgical treatment with adequate SPT demonstrated that stable peri-implant tissue conditions were achieved in many cases, although some patients required further treatment and some implants were lost (Roccuzzo et al., 2017) .
A randomized clinical trial investigating the use of EMD for the management of peri-implantitis showed that the use of EMD did not result in improved PDs and BoP after 12 months (Isehed et al., 2016) . 
F I G U R E 4 Sites with BoP/Suppuration at different periods of review
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This study, however, suggested a potential use of EMD in peri-implantitis management by reporting that the adjunctive use of EMD was associated with increased marginal bone levels and increased prevalence of Gram positive/aerobic bacteria after 12 months of healing.
| Osteogenic properties of enamel matrix derivative
The effectiveness of enamel matrix derivative (EMD) in the treatment of gingival recession and periodontal defects is widely reported (Parashis, Andronikaki-Faldami, & Tsiklakis, 2004) , demonstrating a clear positive effect on soft tissue healing. However, the effectiveness of EMD in treating peri-implantitis, and in particular its role in peri-implant bone regeneration, is still unclear. It was demonstrated in an in vitro study that EMD significantly increased alkaline phosphatase activity and osteocalcin production in MG-63 cells grown on titanium discs, suggesting that EMD may have a positive effect on implant integration (Qu et al., 2011) . In another in vitro study, the capacity of ceramic coated with EMD to influence the formation of hard tissue by mesenchymal and periodontal ligament fibroblasts was assessed (Mrozik, Gronthos, Menicanin, Marino, & Bartold, 2012) . The study showed upregulation of several important bonerelated genes suggesting that EMD may have a potent positive effect on the differentiation of mesenchymal cells to mature bone cells in vitro (Mrozik et al., 2012) . In a study evaluating the effect of EMD on the attachment, proliferation and differentiation of osteoblasts on titanium in vitro, it was concluded that coating titanium with EMD enhances proliferation and differentiation of osteoblasts, suggesting the potential use of this product in bone regeneration, particularly on implants affected by peri-implantitis (Miron et al., 2010) .
Nevertheless, although our study suggests that EMD may be beneficial to bone formation within the peri-implant defect, the literature is unclear about the osteogenic potential of EMD. In support of our findings, a histomorphometric study in dogs showed that EMD, when combined with a membrane, positively influenced bone healing in dehiscence-type defects around implants when compared to EMD alone (Casati, Sallum, Nociti-Jr, Caffesse, & Wilson Sallum, 2002) . On the other hand, the use of EMD and deproteinized bovine bone mineral (DBBM) with GBR did not enhance the amount of bone formation in mandibular jaw defect in rats (Donos et al., 2005) and did not contribute to bone formation around titanium implants in a rabbit model (Franke Stenport & Johansson, 2003) . Therefore, the pro-osteogenic effectiveness of EMD requires further investigation in pre-clinical and clinical models.
| Implant surface debridement and decontamination
Numerous implant surface decontamination techniques and ma- Based on the favourable clinical outcomes reported, it appears that this protocol is effective in decontaminating the implant surface and the associated defect, facilitating the resolution of the peri-implant inflammation.
Ultrasonic instrumentation was used in this study based on its widespread clinical availability, established effectiveness in biofilm removal around teeth, time-effectiveness and ability to access the diseased surfaces. It has been demonstrated that there were no significant differences in the clinical parameters measured following peri-implantitis treatment when titanium hand instruments were compared with ultrasonic instrumentation (Renvert et al., 2009 ).
Furthermore, the use of EDTA in our study is supported by the findings of Roccuzzo et al. (2011) and Roccuzzo et al. (2016) 
| Supportive periodontal therapy
It has been demonstrated that when surgical and regenerative management of peri-implantitis is followed by regular SPT, a majority of the implants affected can be maintained over the long term (HeitzMayfield et al., 2016) . It was also demonstrated that the complete health and absence of bleeding at all sites of the treated implant is harder to achieve in the long term (Heitz-Mayfield et al., 2016) . In the present study, there was a tendency towards recurrence of bleeding on probing (50% of treated implants) when the SPT interval was set at 6 months, as was the case between the 6 and 12-month followup. The percentage of implants with bleeding on probing reduced to 20% when the SPT was subsequently reduced to a 4 monthly period.
This suggests that the dental implants treated in the study are at a high risk of recurrence of inflammation if the supportive therapy is extended longer than 4 months. Furthermore, the same 20%-30% of patients demonstrated persistent bleeding on probing throughout the 36 months period of the study suggesting a possible phenotype of patients or type of implants that are susceptible to inflammation recurrence after surgical therapy for peri-implantitis.
The probing depth reduction and bone fill were considerable with the "cocktail" protocol used in the present study, showing the effectiveness of this approach for regenerative therapy of peri-implantitis. Whether the radiographic bone fill reflects the establishment of new bone-implant contact cannot be ascertained from the present study. The potential of peri-implantitis affected implants to achieve re-osseointegration can only be inferred from available animal studies that showed the possibility of "re-integration" after peri-implantitis therapies (Persson, Berglundh, Lindhe, & Sennerby, 2001; Schou et al., 2003) . More recently, histological assessment of a single case has provided proof-of-concept evidence that re-osseointegration is possible in humans (Fletcher et al., 2017 ).
This cohort study shows that the described protocol, using a combination of DBBMC, EMD and Doxycycline, is effective in the regenerative therapy of peri-implantitis. However, it only reports on the single treatment protocol without any comparison/control groups, and hence, it is not possible to determine the relative contributions of the various "cocktail" components on the treatment outcomes. This is a drawback of the study, and the relative contributions of the various components of the "cocktail" need to be explored in controlled long-term randomized clinical trials.
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